Bizaxofusp (MDNA55): IL-4 Superkine Therapy for High-Grade Glioma
Bizaxofusp (MDNA55) is a first-in-class IL-4 Superkine therapy that selectively targets myeloid-derived suppressor cells, which accumulate in tumors and drive immunosuppression. IL-4R is highly expressed in both malignant brain tumors as well as the immunosuppressive tumor microenvironment, but not healthy brain tissue, making IL-4R a highly attractive target to elicit strong anti-tumor activity with minimal off-target toxicity.
Once the immunosuppressive tumor microenvironment is disrupted, bizaxofusp induces immunogenic cell death in tumor cells, which results in the release of tumor antigens and danger signals that alert the immune system to initiate a robust immune response. This process has the potential to provide ongoing immune surveillance and tumor-killing even after the drug has been cleared.
Bizaxofusp is Phase 3–ready, and we are currently seeking strategic partners to co-develop this promising, potentially first-in-class therapy for patients with high-grade glioma and other IL-4R–expressing tumors.